natgillin/translations-raw huggingface dataset:
Overhold nøje lægens anvisninger vedrørende dosering, kontrol (blod- og urinprøver), kostplan og fysisk aktivitet (fysisk arbejde og motion).
Follow closely the instructions for dosage, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.
Overhold nøje lægens anvisninger vedrørende dosering, kontrol (blod- og urinprøver), kostplan og fysisk aktivitet (fysisk arbejde og motion).
Follow closely the instructions for dosage, monitoring (blood and urine tests), diet and physical activity (physical work and exercise), injection technique as discussed with your doctor.
Overhold nøje lægens anvisninger vedrørende dosering, kontrol (blod- og urinprøver), kostplan og fysisk aktivitet (fysisk arbejde og motion).
Follow closely the instructions for dose, monitoring (blood and urine tests), diet and physical activity (physical work and exercise), injection technique as discussed with your doctor.
Overholdelse af anbefalet follitropin alfa dosis og administrationsregime samt nøje overvågning af behandlingen vil reducere risikoen for disse bivirkninger.
Adherence to the recommended follitropin alfa dosage and regimen of administration, and careful monitoring of therapy will minimise the incidence of such events.
Overholdelse af anbefalet GONAL-f dosis og administrationsregime samt nøje overvågning af behandlingen vil reducere risikoen for disse bivirkninger.
Adherence to recommended GONAL-f dose and regimen of administration, and careful monitoring of therapy will minimise the incidence of such events.
Overholdelse af anbefalet Pergoveris- og FSH-dosis og administrationsregime kan minimere risikoen for hyperstimulation af ovariet.
Adherence to recommended Pergoveris and FSH dosage and regimen of administration can minimise the risk of ovarian hyperstimulation .
Overholdelsen af tilskudsregimet bør verificeres ved regelmæssige planlagte besøg, og vigtigheden heraf bør understreges.
Compliance with the supplementation regimen should be verified at regular scheduled appointments and the importance emphasised.
Overhydrering skal undgås hos patienter med risiko for hjertesvigt.
Overhydration should be avoided in patients at risk of cardiac failure.
Overhydrering skal undgås ved patienter med risiko for hjerteinsufficiens.
Overhydration should be avoided in patients at risk of cardiac failure.
Overhydrering, hypomagnesiæmi, anoreksi, elektrolytforstyrrelser, hyperglykæmi, hypokalcæmi, metabolisk acidose
fluid overload, hypomagnesaemia, anorexia, electrolyte imbalance, hyperglycaemia, hypocalcaemia, metabolic acidosis
Overhætte
Over-cap
Overhætten drejes og tages af, og spidshætten drejes og tages af.
Twist and pull off Over-cap and Tip-cap.
OVERIGE
OTHER
overlagt forsøg på at skade på sig selv
deliberate injury to oneself
Overledningsforstyrrelser Sinusarytmi
Cardiac conduction disorders
Overlegenheden ved tipranavir indplus lavdosis ritonavir i forhold til komparator- proteasehæmmer/ritonavir-gruppen sås efter 48 uger for alle effektparametre.
The superiority of tipranavir co-administered with low dose ritonavir over the comparator protease inhibitor/ritonavir arm was observed for all efficacy parameters at week 48.
Overlevelse
Overall Survival
Overlevelse efter 1 år var 29 % [95 % CI: 12 % – 45 %].
Survival at one year was 29 % [95 % CI: 12 %–45 %].
Overlevelse efter 14 dage, N (%)
Survival at Day 14, N (%)
Overlevelse efter 3 måneder var ligeledes bedre for Xigris- gruppen i forhold til placebo (Log-Rank p=0,048).
Survival through 3 months was also better in the Xigris group compared to placebo (log rank p=0.048).
Overlevelse efter 4 timer, N (%)
Survival at Hour 4, N (%)
overlevelse for
Probability of Survival
Overlevelse hos patienter med WHO-funktionsklasse II ved baseline og ved 1, 2 og 3 år var henholdsvis 97 %, 94 % og 88 %, og for patienter med WHO-funktionsklasse III ved baseline, henholdsvis 97 %, 94 % og 87 %.
Survival in patients of WHO functional class II at baseline at 1, 2 and 3 years was 97%, 94% and 88% respectively, and for patients of WHO functional class III at baseline was 97%, 94% and 87% respectively.
Overlevelse hos patienter med WHO-funktionsklasse II ved baseline og ved 1, 2 og 3 år var henholdsvis 98 %, 96% og 96 %, og for patienter med WHO-funktionsklasse III ved baseline henholdsvis 96 %, 91 % og 87 %.
Survival in patients of WHO functional class II at baseline at 1, 2 and 3 years was 98%, 96% and 96% respectively, and for patients of WHO functional class III at baseline was 96%, 91% and 87% respectively.
Overlevelse i alt var også signifikant længere (p = 0,0201) til fordel for TCF- armen med en nedsættelse af risikoen for død på 22,7 %.
Overall survival was also significantly longer (p=0.0201) in favor of the TCF arm with a risk reduction of mortality of 22.7%.
Overlevelse i måneder
Survival time in months
Overlevelse og tumorprogression blev undersøgt i fem store, kontrollerede studier, der omfattede i alt 2.833 patienter, hvoraf de fire var dobbeltblinde placebokontrollerede studier og den femte var et åbent studie.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2,833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Overlevelse og tumorprogression er undersøgt i fem store kontrollerede forsøg med i alt 2 833 patienter, hvoraf fire var dobbeltblinde placebokontrollerede forsøg og et var et åbent forsøg.
Survival and tumour progression have been examined in five large controlled studies involving a total of 2 833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.
Overlevelse og tumorudvikling er blevet undersøgt i fem store kontrollerede forsøg med epoetin alfa, - beta og darbepoetin alfa, med 2833 involverede patienter, hvoraf fire var dobbeltblindede placebokontrollerede forsøg, og et var en ublindet forsøg.
Survival and tumour progression have been examined in five large controlled studies of epoetin alfa, beta and darbepoetin alfa involving a total of 2,833 patients, of which four were double-blind placebo- controlled studies and one was an open-label study.
Overlevelse var bedre i kombinationsarmen med
Survival was superior in the docetaxel + capecitabine combination arm
Overlevelsen blev evalueret hos intent-to-treat-populationen på grundlag af follow-up- overlevelsesdata.
Survival was evaluated in the intent-to-treat population based on follow-up survival data.
Overlevelsesanalyser i patientundergrupper viste konsistent overlevelsesfordele ved behandling med Xofigo, uafhængigt af totalt basisk fosfatase (BASP), brug af bisfosfonater ved baseline og tidligere anvendelse af docetaxel.
Subgroup survival analysis showed a consistent survival benefit for treatment with Xofigo, independent of total alkaline phosphatase (ALP), use of bisphosphonates at baseline and prior use of docetaxel.
Overlevelsesprocenten var 93,7 % i TAC-armen og 91,4 % i FAC-armen ved tidspunktet for 8-års followup, og 91,3 % i TAC-armen og 89 % i FAC-armen ved tidspunktet for 10-års followup.
The survival rate was 93.7% in the TAC arm and 91.4 % in the FAC arm, at the 8-year follow-up timepoint, and 91.3 % in the TAC arm and 89 % in the FAC arm, at the 10-year follow-up timepoint.
Overlevelsesprocenten var 93,7 % i TAC-armen og 91,4 % i FAC-armen ved tidspunktet for 8-års followup, og 91,3 % i TAC-armen og 89 % i FAC-armen ved tidspunktet for 10-års followup.
The survival rate was 93.7% in the TAC arm and 91.4% in the FAC arm, at the 8-year follow-up timepoint, and 91.3% in the TAC arm and 89% in the FAC arm, at the 10-year follow-up timepoint.
Overlevelsesrate efter et år
One-year survival rate
Overlevelsesstatus er blevet vurderet i en opfølgningsundersøgelse med overlevende fra PROWESS- studiet.
Survival status was assessed in a follow-up study of PROWESS survivors.
Overlevelsesstatus for hospitalsindlagte samt overlevelsesstatus efter 3 måneder var rappor- teret for henholdsvis 98 % og 94 % af de 1690 PROWESS-patienter.
In-hospital and 3 month survival status was reported for 98% and 94% of the 1690 PROWESS subjects respectively.
Overlevelsestid (uger)
Survival Time (weeks)
Overlevet til dag 180
Survived to day 180
Overordnet
Overall
Overordnet begreb (high level term)
GGT), weight increasede, heart rate increasede, CPK
Overordnet begreb (high level term)
Injury, poisoning and procedural complications
Overordnet genfinding af lægemiddelstofrelateret materiale efter fem daglige doser af topotecan var 71 til 76 % af den administrerede intravenøse dosis.
Overall recovery of medicinal product-related material following five daily doses of topotecan was 71 to 76 % of the administered IV dose.
Overordnet genvinding af lægemiddelstofrelateret materiale efter fem daglige doser af topotecan var 71 til 76 % af den administrerede intravenøse dosis.
Overall recovery of medicinal product-related material following five daily doses of topotecan was 71 to 76 % of the administered IV dose.
Overordnet gjorde undersøgelsen det ikke muligt at konkludere noget om forskellene mellem Aubagio og interferon beta- 1a til behandling af multipel sklerose.
Overall, no conclusion could be reached from this study on any differences between Aubagio and interferon beta-1a for MS treatment.
Overordnet ITT
Overall ITT
Overordnet ITT Median (måneder)
Overall ITT Median (months)
Overordnet klinisk responsa.
Major Clinical Responsea.
Overordnet overlevelse var også signifikant længere (p = 0,0201) til fordel for TCF-armen med en reduktion af risikoen for mortalitet på 22,7 %.
OS was also significantly longer (p = 0.0201) in favor of the TCF arm with a risk reduction of mortality of 22.7%.
Overordnet respons
Overall
Overordnet respons (stratificeret ved baseline-hiv- 1-RNA)
Overall response (stratified by baseline HIV-1 RNA)
Overordnet responsgrad (%)
Overall Response Rate (%)
Overordnet resulterer kombinationen af vernakalants effekt på de kardielle kalium- og natriumkanaler i en væsentlig antiarytmisk effekt, som hovedsageligt er koncentreret i atrierne.
Overall, the combination of effects of vernakalant on cardiac potassium and sodium currents results in substantial antiarrhythmic effects that are mainly concentrated in the atria.
Overordnet set forekommer sikkerhedsprofilen ensartet i alle de udførte kliniske undersøgelser.
Overall, the safety profile appears consistent across all the clinical studies conducted.
Overordnet set resulterede crizotinib i fordele for den generelle livskvalitet, idet der sås signifikant større forbedring fra baseline i crizotinib-armen sammenlignet med kemoterapi-armen (cyklus 2 til 20, p < 0,05).
Crizotinib resulted in overall global quality of life benefits with a significantly greater improvement from baseline observed in the crizotinib arm compared to the chemotherapy arm (Cycles 2 to 20; value <0.05).
Overordnet svarede sikkerhedsprofilen for Pegasys i kombination med ribavirin hos tidligere ikke- responderende patienter til den hos naive patienter.
Overall, the safety profile for Pegasys in combination with ribavirin in prior non-responder patients was similar to that in naïve patients.
Overordnet udgjorde den yderligere reduktion 0,58 procentpoint ved brug af kombinationen med 5 mg empagliflozin to gange dagligt, og 0,62 procentpoint med 12,5 mg.
Overall, the additional reduction was 0.58 percentage points with a combination providing 5 mg of empagliflozin twice daily, and 0.62 percentage points with the
Overordnet var der ingen klinisk relevant forskel mellem Ilaris’ profil med hensyn til effekt, sikkerhed og tolerabilitet hos pædiatriske patienter sammenlignet med den overordnede CAPS-population.
Overall, there were no clinically meaningful differences in the efficacy, safety and tolerability profile of Ilaris in paediatric patients compared to the overall CAPS population.
Overordnet var der ingen klinisk relevant forskel mellem sikkerheds- og tolerabilitetsprofilen for Ilaris hos pædiatriske patienter sammenlignet med den samlede CAPS-population (bestående af voksne og pædiatriske patienter, N=211), inklusive de infektiøse episoders overordnede hyppighed og sværhedsgrad.
Overall, there were no clinically meaningful differences in the safety and tolerability profile of Ilaris in paediatric patients compared to the overall CAPS population (comprised of adult and paediatric patients, N=211), including the overall frequency and severity of infectious episodes.
Overordnet var Faslodex, med en dosis på 250 mg månedligt, mindst lige så effektiv som anastrozol, når man så på progressionsfri overlevelse, objektivt respons og tid indtil død.
Overall, Faslodex at the 250 mg monthly dose was at least as effective as anastrozole in terms of progression- free survival, objective response, and time to death.
Overordnet var hyppigheden og typen af bivirkninger næsten ens for Plenadren-tabletter med modificeret udløsning givet én gang daglig og hydrocortison-tabletter givet tre gange daglig i et 12-ugers forsøg.
Overall, the frequency and type of adverse reactions were similar for Plenadren once daily modified- release tablets and hydrocortisone tablets given three times daily in a 12-week study.
Overproduktion af skjoldbruskkirtlens hormoner, hvilket medfører øget stofskifte i hvile.
Overproduction of thyroid hormones which increases the amount of energy the body uses at rest.
Oversigt over administration af HyQvia
HyQvia administration scheme
Oversigt over andre bivirkninger
List of other side effects
Oversigt over andre bivirkninger Ikke almindelig bivirkninger
List of other side effects Uncommon side effects
Oversigt over antitumor-effekt for kombinations- og monoterapistudier
Antitumour efficacy summary for combination and single-agent studies
Oversigt over bivirkninger
Summary of adverse reactions
Oversigt over bivirkninger
Summary of the safety profile
Oversigt over bivirkninger
Tabulated list of adverse reactions
Oversigt over bivirkninger
Tabulated lists of adverse reactions
Oversigt over bivirkninger, opstillet i tabelform
Tabulated list of adverse reactions
Oversigt over dele
After use
Oversigt over den nødvendige tiltag
Summary of action required
Oversigt over forsøgsdesign
Summary of study design
Oversigt over indholdssedlen:
What is in this leaflet:
Oversigt over indlæ gssedlen
What is in this leaflet
Oversigt over indlægsedlen
What is in this leaflet
Oversigt over indlægsseddel:
In this leaflet:
Oversigt over indlægssedlen
In this leaflet:
Oversigt over indlægssedlen
See section 4.
Oversigt over indlægssedlen
What is in this leaflet
Oversigt over indlægssedlen
What is in this leaflet:
Oversigt over indlægssedlen
What is in this leaflet?
Oversigt over indlægssedlen
What is n this leaflet:
Oversigt over indlægssedlen.
What is in this leaflet
Oversigt over indlægssedlen:
In this leaflet
Oversigt over indlægssedlen:
Keep this leaflet.
Oversigt over indlægssedlen:
See Section 4.
Oversigt over indlægssedlen:
What in this leaflet:
Oversigt over indlægssedlen:
What is in this leaflet
Oversigt over indlægssedlen:
What is in this leaflet:
Oversigt over indlægssedlen::
In this leaflet:
Oversigt over instruktionerne for Brimica Genuair
Overview of the instructions for use of Brimica Genuair
Oversigt over instruktionerne for Duaklir Genuair
Overview of the instructions for use of Duaklir Genuair
Oversigt over klinisk udfald bedømt ved sponsordefineret test-of-cure.
Summary of sponsor-defined clinical outcome at test-of-cure:
Oversigt over klinisk virkning
Overview of clinical efficacy
Oversigt over kombinationsbehandling i tabelform
Tabulated summary for combination therapy
Oversigt over overlevelse, responsrate og tid til progression hos SCLC-patienter, der er behandlet med oral HYCAMTIN eller intravenøs HYCAMTIN
Summary of survival, response rate, and time to progression in SCLC patients treated with oral HYCAMTIN or intravenous HYCAMTIN
Oversigt over prøver for autoimmune tilstande:
Summary of tests you will have for autoimmune conditions:
Oversigt over sikkehedsprofilen
Summary of the safety profile
Oversigt over sikkerhedsprofilen
a- Summary of the safety profile
Oversigt over studieresultaterne
Summary of study results
Oversigt over svære eksacerbationer i kliniske studier
Overview of severe exacerbations in clinical studies
Overskrid ikke den anbefalede dosering, og anvend IntronA så længe som ordineret.
Do not exceed the recommended dosage, and take IntronA for as long as prescribed.
Overskrid ikke den anbefalede samlede daglige dosis (5 mængder på størrelse med en ært).
Do not exceed the total daily recommended dose (5 pea size amounts).
Overskrid ikke en maksimal daglig dosis på 150 mg.
A dose of 150 mg daily must not be exceeded.
overskride 200 mg.
not exceed 200 mg.
Overskrides doseringstidspunktet med mere end 5 timer, bør patienten informeres om at vente til det næste planlagte doseringstidspunkt for Aptivus og ritonavir.
If a dose is missed by more than 5 hours, the patient should be instructed to wait and then to take the next dose of Aptivus and ritonavir at the regularly scheduled time.
Overskrides doseringstidspunktet med mindre end 5 timer, skal patienten instrueres i at tage den glemte dosis med det samme og tage den næste Aptivus- og ritonavirdosis som planlagt.
If a dose is missed by less than 5 hours, the patient should be instructed to take the missed dose immediately, and then to take the next dose of tipranavir and ritonavir at the regularly scheduled time.
Overskud 13C:- Forskel mellem præ- og post-urea-prøvemålinger.
Excess 13C:- Difference between pre- and post-urea sample measurements.
Overskud- det er 12,5 µg for at muliggøre testning af den radiokemiske renhed og for at sikre, at der kan indgives 50 µg tilmanocept.
The overfill is 12.5 micrograms to allow for radiochemical purity testing and to ensure that 50 micrograms of tilmanocept can be delivered.
Overskydende injektionsvæske bør smides ud med det samme efter injektionen.
The residual volume should be discarded immediately after the injection.
overskydende protein i urinen (proteinuri) skader på milten
excess protein in the urine (proteinuria) rupture of the spleen
Overskydende vand rystes af, og den usamlede orale sprøjte lades tørre, indtil den skal samles, næste gang den skal bruges til dosering.
Shake off excess water and leave the disassembled oral syringe to dry until reassemble for next dosing occasion.
Overskydende volumen skal fjernes før injektion.
The excess volume should be expelled before injecting
Overskydende volumen skal fjernes inden injektion.
Excess volume should be expelled prior to injection.
Overskydende volumen skal fjernes.
Excess volume to be expelled.
Overspisning (spise store mængder mad på kort tid) eller tvangsspisning (spise mere mad end normalt og mere end nødvendigt for at stille sulten).
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than needed to satisfy your hunger).
Overspisning (spiser store mængder mad på kort tid) eller tvangsspisning (spiser mere mad end normalt og mere end nødvendigt for at tilfredsstille din sult)
Binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)
Overspring den glemte dosis.
Skip the missed dose.
Oversprungen dosis
Missed dose
Oversprunget månedlig vedligeholdelsesdosis (> 6 måneder)
Missed monthly maintenance dose (> 6 months)
oversprungne måltider,
missed meals,
Overstimulation af æggestokkene (OHSS)
Ovarian hyperstimulation syndrome (OHSS)
Oversuppression af immunsystemet kan også øge modtageligheden for infektion, herunder oppor- tunistiske infektioner (bakteriel, svamp, viral og protozoal), livstruende infektioner og sepsis.
Oversuppression of the immune system can also increase susceptibility to infection, including opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections, and sepsis.
overtrukket tablet
Coated tablet
Overtrukne tabletter
Coated Tablets
Overtræk
Coating
Overtræk
Film coat
Overtræk Hypromellose (E464) Rød jernoxid (E172) Lactosemonohydrat Triacetin (E1518) Titandioxid (E171)
Film-coating Hypromellose (E464) Iron oxide red (E172) Lactose monohydrate Triacetin (E1518) Titanium dioxide (E171)
Overtræk Hypromellose Macrogol Titandioxid
Coating Hypromellose Macrogol Titanium dioxide
Overtræk Sort jernoxid Rød jernoxid
Film-coating Iron oxide black Iron oxide red Macrogol 3350
Overtræk: Film:
Film:
Overtræk: Hydroxypropylcellulose (E463) Titandioxid (E171)
Film coating: Hydroxypropylcellulose (E463) Titanium dioxide (E171)
Overtrækket for 24 mg/26 mg og 97 mg/103 mg tabletterne indeholder hypromellose, titandioxid (E171), Macrogol 4000, talcum, rød jernoxid (E172), og sort jernoxid (E172).
The 24 mg/26 mg and the 97 mg/103 mg tablet coatings contain hypromellose, titanium dioxide (E171), Macrogol 4000,talc, iron oxide red (E172) and iron oxide black (E172).
Overtrækket for 49 mg/51 mg tabletten indeholder hypromellose, titandioxid (E171), Macrogol 4000, talcum, rød jernoxid (E172) og gul jernoxid (E172).
The 49 mg/51 mg tablet coating contains hypromellose, titanium dioxide (E171), Macrogol 4000, talc, iron oxide red (E172) and iron oxide yellow (E172).
Overvej  afbrydelse
Consider  interruption
Overvej altid, om der er opstået tekniske problemer, hvis du for at nå det ønskede blodsukker skal:
You should always consider the possibility of a technical problem if, in order to achieve the desired blood sugar levels,
Overvej at fordoble rifabutin- dosis i regimer, hvor rifabutin gives 2 eller 3 gange om ugen i kombination med Atripla.
Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week in combination with Atripla.
Overvej at genstarte næste planlagte behandling med 1 dosisniveaureduktiona a Se tabel 4 vedrørende dosisreduktion
Consider restarting the next scheduled treatment at 1 dose level reductiona a See table 4 for dose level reductions
Overvej at seponere Iclusig
Consider discontinuing Iclusig
Overvej at tilbageholde IMBRUVICA midlertidigt.
Consider temporarily holding IMBRUVICA.
Overvej brug af kolonistimulerende faktor før næste serie.
Consider use of colony- stimulating factor prior to next cycle.
Overvej fordobling
Proguanil:
Overvej nøje fordele og risici før administration af dabrafenib til patienter med tidligere eller nuværende cancer, som er associeret med RAS-mutationer.
Carefully consider benefits and risks before administering dabrafenib to patients with a prior or concurrent cancer associated with RAS mutations.
Overvej patientens fulde anamnese, herunder evt. tidligere eller samtidig brug af biologiske lægemidler
Consider the patient’s full medical history, including any prior or concurrent biological medicine use
Overvej permanent seponering
Consider permanent discontinuation
Overvej tyggetabletter, hvis barnet eller den unge ikke er i stand til at sluge en tablet.
If unable to swallow a tablet, consider the chewable tablet.
Overvej understøttende behandling som indiceret.
Consider adding supportive care as indicated.
Overvej, om du kan køre bil i sådanne situationer.
The advisability of driving should be considered in these circumstances.
Overveje behov for månedlig ordination for at kunne sikre, at patienter og testresultater bliver vurderet inden næste ordination.
Should consider monthly prescription of 30 day supply to ensure that patients and key test results are reviewed prior to further prescription.
Overvejelser angående hjælpestoffer
Excipient related considerations
Overvejelser i forbindelse med fastsættelse af dosis
Dose management considerations
Overvejelser med henblik på hjælpestoffer
Excipient related considerations
Overvejelser vedrørende brug hos særlige populationer
Considerations for use in particular populations
Overvejelser vedrørende hjælpestoffer
Excipient related considerations
overvejes (4 kapsler/~ 6,5 ml to
(4 capsules/~6.5 ml twice daily
overvejes at justere
midazolam should be considered,
overvejes at starte med den
Consider starting with the
overvejes – især hvis der anvendes
midazolam should be considered, especially if
overvejes, og elektrokardiografisk
should be considered, and
overvejes, såsom azithromycin.
azithromycin, should be considered.
overvejes.
be considered.
overvejes.
be envisaged.
overvejes.
Clinical Comments